Press releases

JSR Life Sciences and GlycoSeLect Enter Licensing and Joint Development Agreement

Sunnyvale, CA, ‐ October 31, 2019 JSR Life Sciences announced today that it has signed a technology licensing and joint development agreement with Dublin, Ireland-based GlycoSeLect, which provides recombinant prokaryotic lectins (RPLs) that enable the selective isolation of glycosylated biomolecules.  The agreement will focus on the development of a glyco-affinity ligand and capture resin.

Read more Read more about JSR Life Sciences and GlycoSeLect Enter Licensing and Joint Development Agreement

PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography

TOKYO, JAPAN – September 20, 2019 - JSR Corporation and PeptiDream Inc. have agreed to begin a joint development program to identify peptides applicable to the affinity chromatography*1 process used in the purification of biopharmaceuticals such as antibody therapeutics.

Read more Read more about PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography

JSR Life Sciences, LLC Expands through East Coast Center of Excellence

Sunnyvale, CA – July 11, 2019 – JSR Life Sciences, LLC announced today that it has expanded its footprint and technical capabilities through the opening of its Applications Center of Excellence in Durham, NC.  The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training. 

Read more Read more about JSR Life Sciences, LLC Expands through East Coast Center of Excellence

JSR Completes its Amsphere™ A3 Capacity Expansion

Leuven, Belgium – May 17, 2018 – JSR Life Sciences (JLS) is pleased to announce that it has completed its capacity expansion for production of its Amsphere™ A3 protein-A chromatography resin in Leuven, Belgium. The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.  

Read more Read more about JSR Completes its Amsphere™ A3 Capacity Expansion

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies

Read more Read more about JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences Expands Manufacturing Capabilities at KBI Biopharma

Durham, NC - May 23, 2017 - JSR Life Sciences (JLS) today announced that KBI Biopharma (KBI), a subsidiary of JSR Corporation (JSR), is expanding its biopharmaceutical manufacturing capacity and capabilities at both its Durham, North Carolina and Boulder, Colorado facilities.  KBI is investing approximately $30M on the two site expansion projects, which will greatly enhance the offerings at each site and are scheduled for completion later this year.

Read more Read more about JSR Life Sciences Expands Manufacturing Capabilities at KBI Biopharma
1